ClinicalTrials.Veeva

Menu
R

Royal Perth Hospital | Haematology Department - Clinical Trials Unit

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Azacitidine
Cytarabine
Venetoclax
Zanubrutinib
cyclophosphamide
Interferon
Bendamustine
Lenalidomide
Selonsertib
TDF

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

53 of 265 total trials

4D-310 in Adults With Fabry Disease and Cardiac Involvement

This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a s...

Active, not recruiting
Fabry Disease
Biological: 4D-310

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to i...

Invitation-only
Waldenstrom Macroglobulinemia
Follicular Lymphoma
Drug: Ibrutinib
Status recently updated

This study is a Phase 1, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics,...

Enrolling
Active, not recruiting
Acute Myeloid Leukemia
Biological: WU-NK-101

Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously a...

Enrolling
Relapsed/Refractory Multiple Myeloma
Drug: Carfilzomib
Drug: Dexamethasone

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: MGL-3196

This is a phase III, randomized, open-label, multicenter trial, conducted in Sweden, Norway, Finland, Denmark, Italy, Australia and New Zealand, in e...

Enrolling
DLBCL
Diffuse Large B Cell Lymphoma
Drug: R-pola-mini-CHP
Drug: R-mini-CHOP

he purpose of the study is to evaluate the efficacy, safety, and tolerability BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants wi...

Active, not recruiting
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
Drug: Obinutuzumab
Drug: Zanubrutinib

To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Rituximab
Drug: Venetoclax

A study designed to evaluate the safety of crovalimab with eculizumab in participants with PNH currently treated with complement inhibitors. This stu...

Active, not recruiting
Paroxysmal Nocturnal Hemoglobinuria
Drug: Eculizumab
Drug: Crovalimab

This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy and PK of APG-2575 in combination with Azacitidin...

Enrolling
AML, Adult
Drug: APG 2575 ramp up arm

This is a Phase 2 open-label extension study to evaluate the long-term safety, tolerability, and clinical activity of AT-02.AT-02 is an investigation...

Enrolling
Amyloidosis; Systemic
Drug: AT02

This is a study of venetoclax, daratumumab, and dexamethasone with and without bortezomib combination therapy to evaluate safety, tolerability, and e...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Bortezomib

The purpose of this study is to determine the efficacy of cusatuzumab in combination with azacitidine in participants with previously untreated acute...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Cusatuzumab
Drug: Azacitidine

The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety o...

Enrolling
Perianal Crohns Disease
Fistulizing Crohns Disease
Drug: Guselkumab
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of JNJ-75276617 in Part 1 (Dose Escalation) and to determine sa...

Enrolling
Acute Leukemias
Acute Lymphoblastic Leukemia
Drug: JNJ-75276617

Heart attacks are caused by a blood clot blocking the blood vessels of the heart, preventing blood getting to the heart muscle. Opening up the artery...

Enrolling
Elevated IMR (>32)
STEMI
Drug: Tenecteplase (1/3 systemic weight based dose)
Other: Sterile water for injection (WFI)

The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R\[s\]) and schedule for the study treatment (Part 1), to characteriz...

Enrolling
Multiple Myeloma
Drug: Daratumumab
Drug: Teclistamab

Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). Successful...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Azacitidine

Trial sponsors

Gilead Sciences logo
T
AbbVie logo
BeiGene logo
Actelion Pharmaceuticals logo
E
A
K
Abbott logo
Janssen (J&J Innovative Medicine) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems